Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 28Gastrointestinal Stromal Tumors 4Colonic Neoplasms 4Carcinoma, Hepatocellular 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasms 3Neoplasm Metastasis 3Rectal Neoplasms 2Gallbladder Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Bile Duct Neoplasms 2Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer) 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Sarcoma 1Rhabdomyosarcoma 1Renal Insufficiency 1Physician Education 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Noonan Syndrome 6 1Metastatic Pancreatic Adenocarcinoma 1Melanoma 1Liver Neoplasms 1Liposarcoma 1Insulinoma 1

Interventions

regorafenib 1napabucasin 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Gastrointestinal Cancer × regorafenib × Clear all
NCT02024607 2023-11-15

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

Sumitomo Pharma America, Inc.

Phase 1/2 Completed
495 enrolled 18 charts
Gastrointestinal

Advanced Gastrointestinal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡